S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Gautam Borthakur,Jorge E. Cortes,Elihu E. Estey,Elias Jabbour,Stefan Faderl,Susan O'Brien,Guillermo Garcia-Manero,Tapan M. Kadia,Xuemei Wang,Keyur P. Patel,Rajyalakshmi Luthra,Charles Koller,Mark Brandt,Farhad Ravandi,Hagop M. Kantarjian +14 more
TL;DR: The data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.
Journal ArticleDOI
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
Courtney D. DiNardo,Keyur P. Patel,Guillermo Garcia-Manero,Rajyalakshmi Luthra,Sherry Pierce,Gautam Borthakur,Elias Jabbour,Tapan M. Kadia,Naveen Pemmaraju,Marina Konopleva,Stefan Faderl,Jorge E. Cortes,Hagop M. Kantarjian,Farhad Ravandi +13 more
TL;DR: Despite the clinically signifi cant prognostic information gained through identifi cation of epigenetic mutations, less insight is currently available to determine how these mutations should be considered for therapeutic decisions.
Journal ArticleDOI
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion
Paolo Strati,Michael J. Keating,Susan O'Brien,Alessandra Ferrajoli,Jan A. Burger,Stefan Faderl,Francesco Paolo Tambaro,Nitin Jain,William G. Wierda +8 more
TL;DR: New first-line strategies and agents must aim at both improving response and maintaining remission in patients with deletion 17p, particularly in the presence of complex karyotype.
Journal ArticleDOI
Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
Hagop M. Kantarjian,Susan O'Brien,Jorge E. Cortes,Francis J. Giles,Jianqin Shan,Mary Beth Rios,Stefan Faderl,Srdan Verstovsek,Guillermo Garcia-Manero,William G. Wierda,Steven M. Kornblau,Alessandra Ferrajoli,Michael J. Keating,Moshe Talpaz +13 more
TL;DR: This analysis provides evidence for a survival advantage with imatinib versus other therapies in chronic-phase CML post-IFN failure, and for a surviving advantage with Imatinib vs IFN in late chronic- phase CML.
Journal ArticleDOI
A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia
Alfonso Quintás-Cardama,Naval Daver,Hawk Kim,Courtney D. DiNardo,Elias Jabbour,Tapan M. Kadia,Gautam Borthakur,Sherry Pierce,Jianqin Shan,Marylou Cardenas-Turanzas,Jorge E. Cortes,Farhad Ravandi,William G. Wierda,Zeev Estrov,Stefan Faderl,Yue Wei,Hagop M. Kantarjian,Guillermo Garcia-Manero +17 more
TL;DR: A prognostic model specifically for patients with t-MDS that predicted overall survival and leukemia-free survival is devised and might facilitate the development of risk-adapted therapeutic strategies.